Amarin Corporation plc - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Amarin Corporation plc is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA internationally. A pivotal event in this period was the June 24, 2025, execution of an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA in 59 European countries. This strategic shift triggered a Global Restructuring Plan to eliminate commercial roles in Europe.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $49.7 million | $42.3 million | $164.4 million | $166.3 million |
| Product Revenue | $48.6 million | $41.9 million | $136.2 million | $144.5 million |
| Licensing & Royalty Revenue | $1.1 million | $0.4 million | $28.2 million | $21.8 million |
| Gross Margin | $22.2 million (45%) | $16.3 million (38%) | $97.7 million (59%) | $90.9 million (55%) |
| Operating Loss | $(11.1) million | $(25.2) million | $(43.8) million | $(39.3) million |
| Net Loss | $(7.7) million | $(25.1) million | $(37.6) million | $(33.6) million |
| Cash & Short-Term Investments | $286.6 million (as of Sept 30, 2025) | |||
| Debt | $0 (No outstanding debt) |
Material Changes vs. Prior Period
- Revenue Mix Shift: Q3 2025 total revenue increased 17% year-over-year, driven by a 34% increase in U.S. product revenue ($40.9M vs $30.6M). This was offset by a 48% decline in Rest of World (RoW) product revenue due to the transition of European operations to Recordati.
- Licensing Spike: YTD licensing revenue increased 30% to $28.2 million, primarily due to a $25.0 million upfront payment recognized in Q2 2025 from the Recordati agreement.
- Restructuring Costs: The company incurred $9.4 million in restructuring expenses in Q3 2025 (and $32.2 million YTD) related to the Global Restructuring Plan. There were no such costs in the prior year periods.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 47% in Q3 2025 ($19.7M vs $36.9M) due to the reduction in European commercial staff.
- Improved Margins: Gross margin percentage improved to 45% in Q3 2025 from 38% in Q3 2024, attributed to a change in customer mix and the exit from Medicaid/340B programs in late 2024.
Guidance, Outlook, and Risks
- Strategic Outlook: Management expects the Recordati partnership to generate annual cost savings of approximately $70.0 million. Recordati is now solely responsible for commercializing VAZKEPA in the 59-country European territory.
- U.S. Market: Despite generic competition for the MARINE indication, Amarin maintains a ~51% market share in the U.S. icosapent ethyl market. The company is focusing on maintaining leadership in the REDUCE-IT indication.
- Liquidity: The company holds $286.6 million in cash and short-term investments. Management believes this is sufficient to fund operations for at least one year. A $50 million share repurchase program was approved in 2024 but has not yet commenced.
- Risks:
- Partner Dependency: Future European revenue is contingent on Recordati's commercial success and ability to secure pricing/reimbursement.
- Generic Competition: Continued erosion of the U.S. MARINE indication market share by multiple generic entrants.
- Regulatory: Ongoing patent litigation regarding the REDUCE-IT indication (e.g., Hikma appeal pending at the Supreme Court).
Investor Verification Checklist
- Recordati Transition: Verify the timeline for Recordati assuming full commercial responsibility in Europe and the status of reimbursement negotiations in key markets.
- U.S. Market Share: Monitor Symphony Health data for trends in VASCEPA branded prescriptions versus generic icosapent ethyl prescriptions.
- Restructuring Execution: Track the realization of the projected $70 million in annual cost savings and the remaining restructuring liability ($12.8 million as of Sept 30, 2025).
- Inventory Levels: Review inventory aging, particularly the $184.7 million in current inventory, to assess potential obsolescence risks given the shift in European sales channels.
- Patent Litigation: Monitor the outcome of the Hikma Supreme Court petition regarding the REDUCE-IT patent validity.